Deenik et al (38) reported the case of a young male T-ALL patient with the NUP214-ABL1 fusion gene who was treated with dasatinib monotherapy (70 mg twice daily), while chemotherapy was postponed due to the surgical removal of a ruptured spleen. The gene discussed is NUP214; the disease is acute lymphoblastic leukemia.